Alimera Sciences (Nasdaq:ALIM) - Stock Price, News & Analysis

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

ALIM Stock Overview

A pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals.

ALIM fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Trading at 92% below our estimate of its fair value

Earnings are forecast to grow 62.74% per year

Risk Analysis

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Alimera Sciences, Inc. Competitors

biote

NasdaqGM:BTMD

US$193.3m

Elite Pharmaceuticals

OTCPK:ELTP

US$470.7m

Fulcrum Therapeutics

NasdaqGM:FULC

US$228.4m

Procaps Group

NasdaqGM:PROC

US$224.5m

Price History & Performance

Summary of all time highs, changes and price drops for Alimera Sciences
Historical stock prices
Current Share Price	US$5.54
52 Week High	US$5.65
52 Week Low	US$2.61
Beta	1.25
11 Month Change	-0.89%
3 Month Change	81.64%
1 Year Change	78.14%
33 Year Change	18.12%
5 Year Change	-34.08%
Change since IPO	-96.64%

Recent updates

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Sep 11

Alimera Sciences: Cheap CVR Optionality

Jul 16

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

Jun 18

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Feb 15

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Dec 30

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Oct 13

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Sep 13

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Oct 06

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Sep 20

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Aug 09

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Jul 22

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Jul 08

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

Mar 24

Is Alimera Sciences, Inc. (NASDAQ:ALIM) Worth US$5.7 Based On Its Intrinsic Value?

Nov 06

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Aug 24

Alimera Sciences' (NASDAQ:ALIM) Shareholders Are Down 75% On Their Shares

Feb 11

Alimera Sciences (ALIM) Investor Presentation - Slideshow

Nov 18

Shareholder Returns

	ALIM	US Pharmaceuticals	US Market
7D	0.2%	1.4%	1.1%
1Y	78.1%	19.4%	32.2%

Return vs Industry: ALIM exceeded the US Pharmaceuticals industry which returned 19.2% over the past year.

Return vs Market: ALIM exceeded the US Market which returned 25.3% over the past year.

Price Volatility

Is ALIM's price volatile compared to industry and market?
ALIM volatility
ALIM Average Weekly Movement	22.1%
Pharmaceuticals Industry Average Movement	9.4%
Market Average Movement	6.3%
10% most volatile stocks in US Market	14.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ALIM's share price has been volatile over the past 3 months.

Volatility Over Time: ALIM's weekly volatility has increased from 13% to 22% over the past year.

About the Company

Founded	Employees	CEO	Website
2003	157	Rick Eiswirth	alimerasciences.com

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

Alimera Sciences, Inc. Fundamentals Summary

How do Alimera Sciences's earnings and revenue compare to its market cap?
ALIM fundamental statistics
Market cap	US$301.29m
Earnings (TTM)	-US$15.27m
Revenue (TTM)	US$99.68m

3.0x

P/S Ratio

-19.7x

P/E Ratio

Is ALIM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALIM income statement (TTM)
Revenue	US$99.68m
Cost of Revenue	US$13.57m
Gross Profit	US$86.11m
Other Expenses	US$101.39m
Earnings	-US$15.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.28
Gross Margin	86.39%
Net Profit Margin	-15.32%
Debt/Equity Ratio	179.8%

How did ALIM perform over the long term?

See historical performance and comparison

This company has been acquired

ALIM Stock Overview

Rewards

Risk Analysis

Alimera Sciences, Inc. Competitors

NasdaqGM:BTMD

US$193.3m

OTCPK:ELTP

US$470.7m

NasdaqGM:FULC

US$228.4m

NasdaqGM:PROC

US$224.5m

Price History & Performance

Recent News & Updates

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Alimera Sciences: Cheap CVR Optionality

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

Recent updates

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) completed the acquisition of Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others.

Alimera Sciences: Deal Closing After All, CVR Still Attractive

Alimera Sciences: Cheap CVR Optionality

ANI Pharmaceuticals, Inc. (NasdaqGM:ANIP) signed a definitive agreement to acquire Alimera Sciences, Inc. (NasdaqGM:ALIM) from Caligan Partners Master Fund LP and Caligan Partners Master Fund LP, managed by Caligan Partners, LP and others for approximately $300 million.

Market Still Lacking Some Conviction On Alimera Sciences, Inc. (NASDAQ:ALIM)

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Alimera Sciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Forecast breakeven date pushed back to 2025

Price target increased by 14% to US$8.00

Alimera Sciences, Inc. Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

Alimera Sciences, Inc. Provides Revenue Guidance for the Year 2024

Alimera Sciences, Inc. to Report Q4, 2023 Results on Mar 07, 2024

Alimera Sciences, Inc.'s (NASDAQ:ALIM) Shares Not Telling The Full Story

Alimera Sciences, Inc. Names Elliot Maltz as Chief Financial Officer

Is Alimera Sciences (NASDAQ:ALIM) A Risky Investment?

Alimera Sciences, Inc. Appoints Todd Wood as President of U.S. Operations

Alimera Sciences, Inc Appoints Maggie A. Pax to its Board of Directors

Alimera Announces Scientific Data Highlighting ILUVIEN to Be Presented at the American Academy of Ophthalmology

Third quarter 2023 earnings released: US$0.06 loss per share (vs US$0.75 loss in 3Q 2022)

Alimera Sciences, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Investors Holding Back On Alimera Sciences, Inc. (NASDAQ:ALIM)

Alimera Sciences, Inc. Announces Management Appointments

Is Alimera Sciences (NASDAQ:ALIM) Using Too Much Debt?

New major risk - Shareholder dilution

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Alimera Sciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Alimera Sciences, Inc., Annual General Meeting, Aug 01, 2023

Forecast breakeven date moved forward to 2024

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alimera Sciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Less than half of directors are independent

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS and revenues miss analyst expectations

Alimera Sciences, Inc. Appoints Russell L. Skibsted as Senior Vice President

Alimera Sciences, Inc. Announces Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN®Administration

Price target decreased to US$10.50

Insufficient new directors

Alimera Sciences, Inc. Announces Resignation of J. Philip Jones as CFO, Effective from November 28, 2022

Alimera Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Alimera Sciences, Inc. Announces Paladin Phase 4 Study Confirms ILUVIEN Patients' Reduced Need for Multiple Treatments

Alimera confirmatory trial testing Iluvien in diabetic macular edema patients shows positive data

Alimera's eye inflammation Iluvien injection granted reimbursement in Ireland

Alimera Sciences, Inc. Announces Multiple Abstracts Highlighting ILUVIEN® Real World Data at EURETINA Annual Congress

Alimera granted reimbursement in Portugal for eye inflammation Iluvien injection

Insufficient new directors

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alimera Sciences, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Alimera granted pricing, reimbursement in France for eye inflammation Iluvien injection

Alimera gets Italian nod for its Iluvien injection to treat a form of eye inflammation

Alimera Sciences, Inc., Annual General Meeting, Jul 12, 2022

Alimera Sciences, Inc. Announces that Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to ILUVIEN Use for IOP Outcomes

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast to breakeven in 2024

Alimera Sciences, Inc. to Report Q1, 2022 Results on May 09, 2022